1800 244 735

Helpline (02) 9874 9777

Sleep, cilia and HD

Studies have shown that HD patients tend to get less efficient sleep, fewer hours of sleep, and wake up more times during the night. However, sleep in Huntington’s is under-researched because historically scientists have investigated HD as a disease of movement impairment, and sleep problems don’t seem to have anything to do with movement impairment.

Sleep – what is it good for?

The picture is a lot more complex now. Huntington’s disease clearly involves more of the brain than just structures involved with movement. It now appears that sleep — that evolutionarily dubious activity that takes up one third of our lives — may come into play in important ways.

It’s well known that sleep is indispensable to health and well-being, that with minor sleep deprivation, mood, reasoning ability, and learning suffer; with moderate sleep deprivation, our immune systems are less effective and even our hormones go out of whack. In HD, sleep deprivation may have an even more potent effect.

Sleep may be protective in HD

Some symptoms of HD, like thinking impairment and clumsiness, look a bit like symptoms of chronic sleep deprivation. Scientists now believe that sleep deprivation commonly occurs in HD, hidden among other symptoms, and possibly acting in the progression of the disease.

So far there have been no systematic studies to determine whether sleep deprivation is the cause of any HD symptoms. This is an exciting area of study because if dysfunctional sleep is indeed the cause of some HD symptoms, it becomes a strong contender to be the focus of a treatment.

The treatment of sleep disorders in HD patients has also not yet been systematically studied, but there is actually some evidence that imposing a regular sleep schedule is “protective” in mouse models of HD.

In one study, mice carrying the HD mutation were injected with sleep-inducing drugs every night to force them to sleep. In a (perhaps surprisingly) standard test of learning and memory, researchers placed the mice into water-filled tanks with a light signifying the location of a submerged platform. Since mice would much rather stand on the platform than swim, the researchers could observe how well the mice learned and remembered that “light means platform” by the direction they initially swam on repeated trials.

Scientists believe that this type of learning and memory is tied to brain structures especially affected in HD patients. The sleep-regulated mice performed better on this task, suggesting preservation of these brain structures, or at least their function.

This study is obviously very far removed from being a test of viable treatments in people — it certainly doesn’t tell us that chemically induced sleep would improve the overall health of HD patients. What it does provide is a kernel of evidence that dysfunctional sleep is harmful in the progression of HD.

Sleep hormones help HD mice

One way the body naturally regulates sleep is with a “hormone,” or chemical messenger, called melatonin. Release of melatonin by the brain signals that it’s time to sleep and consequently we feel drowsy.

HD patients have been found to produce less melatonin at night, and in fact this may contribute to the dysfunctional sleep sometimes experienced in HD. To see how melatonin levels might be affecting HD patients, researchers injected Huntington mutation mice with extra melatonin every day. These mice lived longer and showed less brain deterioration than HD mice given a dummy injection.

Is this “protective” effect of melatonin related to its ability to regulate sleep? This is one possible explanation, although a protective effect of melatonin was observed in a plate of HD cells as well, which do not technically sleep. For a more in-depth discussion of this melatonin research in HD, you can read this http://en.hdbuzz.net/057 article on HDBuzz.

We know that in HD, clumps or “aggregates” of a specific protein called “Huntingtin” build up inside brain cells, where they disrupt important cellular processes. For cells, especially the long-lived cells of the brain, getting rid of old and damaged materials is vital, and it seems like this job is not getting done correctly in HD.

How does the brain dispose of garbage?

A new study by Dr. Nedergaard of the University of Rochester, New York, suggests that the value of sleep may lie in helping to clean out the brain. While not focused specifically on HD, the study raises interesting questions about the role sleep plays in diseases like HD.

One way cells get rid of the junk they can’t recycle is to expel it into the fluid between cells, called the “interstitial fluid”. Part of daily bodily maintenance involves clearing out this space, and for most of the body this is taken care of by the lymphatic system — a complex system which acts as both a gutter and a filter for interstitial fluid and is tied to the immune system. A fluid called lymph, which is essentially blood plasma, soaks into body tissues and flushes out waste.

The brain does not have access to the lymphatic system but it still needs to clean between its cells — perhaps more than the rest of the body — so it uses a similar system. The fluid that bathes the brain, called cerebrospinal fluid or CSF for short, does the job of the lymph, flushing out the soiled interstitial fluid.

Dr. Nedergaard’s team wanted to know how well the brain’s natural washing machine could remove some problem proteins and other cellular waste, so they injected some of these substances into the interstitial fluid of mice brains.

When they checked how much of the different substances remained, they were pleased to find that the brain had done a pretty good job of flushing them out. One protein that was surprisingly well cleared out was amyloid-beta, also known as Abeta. Abeta is the main constituent of the big clumps of amyloid protein found between sick neurons in the brains of Alzheimer’s disease patients.

The root cause of Alzheimer’s is still unknown but scientists have long suspected that build-up of Abeta and the resulting clumps between cells called “plaques” may be responsible for poor communication between neurons and the large amount of neuron death observed as the disease progresses. In this way Alzheimer’s disease is quite similar to Huntington’s: both involve clumping of protein that is toxic to surrounding neurons.

The Abeta found dissolved in the interstitial fluid is not the same Abeta bound up in plaques, but there’s some evidence that the amounts of the two are related.

Does this mean that a more efficient job of cleaning up the Abeta dissolved in the interstitial fluid could reduce the amyloid buildup? This remains to be tested. Either way, this is certainly a valuable finding for Alzheimer’s disease researchers, though it only loosely concerns HD.

Taking out the trash each night

Nedergaard and his colleagues’ next query would lead them to a more universally applicable question: that of the function of sleep. They knew from earlier studies that more Abeta is found in the interstitial fluid of awake than in sleeping mice and humans. So they wondered whether Abeta is washed away better during sleep or if just a smaller amount is created.

To test this question, they trained mice to fall asleep while hooked up to testing equipment and repeated their earlier procedure of injecting waste substances into their interstitial fluid. In sleeping mice, the clearing of waste was much more efficient and, remarkably, Abeta was flushed out twice as well as when mice were awake.

What could explain the dramatic effect sleep had on the efficiency of brain cleaning?

One simple explanation is that during sleep some brain cells shrink to increase the area between cells. If this were the case, the river of fluid flowing through brain tissue would be wider, carrying away more trash. A test confirmed that the interstitial space was indeed much larger in the brains of sleeping mice.

This groundbreaking work by Dr. Nedergaard raises a lot of questions. Might the messed up sleep in Alzheimer’s disease be affecting the clearing of protein buildup and contributing to the disease? Might dysfunctional sleep be affecting protein buildup in HD as well? We don’t know yet, but you can bet that scientists are working to find out.

Sleep to the rescue?

These new results may be able to give new context to older findings in HD research. As HDBuzz has previously reported, work from several groups of HD scientists has shown that “cilia” don’t work correctly in HD brains.

Cilia are the microscopic cellular paddles that control the flow of CSF in the brain by beating in synchrony, pushing CSF throughout the brain. In HD the cilia of brain cells are poor paddlers and consequently CSF flow is reduced.

This new study by Nedergaard gives us added perspective on how dysfunctional cilia could be contributing to HD. The question becomes: is there a connection between altered sleep in HD patients and the buildup of harmful clumps of protein in their brains? Furthermore, do these problems have anything to do with the altered function of cilia in HD patient brains?

It’s important to be aware of the limitations of what we can take directly from these studies on sleep and ABeta. For one thing, they were conducted on mice and it’s quite possible that mice brains act differently than human brains during sleep. Also, none of Dr. Nedergaard’s studies were directed at HD, which involves the buildup of a specific protein inside of a cell, not outside cells. Thus, how much this information affects what we know about HD definitely remains to be seen.

With these caveats in mind, it’s totally worth getting excited about the many new scientific questions raised by this work. New dotted lines have formed — they’re just waiting to be filled in or erased.

Latest Research Articles

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Published date: 9 December, 2022

The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment in Huntington’s disease (HD). This news comes following recent bad news about side effects of branaplam in HD patients, being tested in the VIBRANT-HD clinical trial, dosing of which was ... Read more

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more